Psychedelics Investing

Psychedelics 2024: Veterans Blessing, Mental Health Paradigm Shift, Providers Training, Ketamine-MDMA Bonds & More
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
Podcast - Post-Frenzy Psychedelics Investing And Reclaiming The Right To Pursue Happiness With Zappy Zapolin: '2024 Is When It Goes Mainstream'
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
Podcast - Post-Frenzy Psychedelics Investing And Reclaiming The Right To Pursue Happiness With Zappy Zapolin: '2024 Is When It Goes Mainstream'
Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More

Psychedelics Investing Recent News

Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More
John Lennon Remembered 43 Years After His Murder In New York, Psychedelic Adventures & Enduring Legacy
Psyched: Cybin's Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney's Memoir And More
Cybin Officially Owns Small Pharma, Gets Three New International Patents Granted
Cybin's FY2023 Financials, Guidance And Appointment Of Sanford R. Climan As Strategic Advisor
Psychedelics biopharma company Cybin Inc. (NYSE: CYBN) shared its financial results for the fiscal year ended this March 31 as well as recent business highlights. Numbers show: Total cash of $12.5 (CA$16.6) million by March 31, 2023.
Psyched: Dubai Psychedelics Event, Key Receptor Discovered, Drew Barrymore, Oprah's Guest, Swiss MDMA & More
Science Conference In Dubai, UAE Hosts Discussion On Psychedelics Research
Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More
Microdosing LSD For Major Depression Treatment Seeks Further Clinical Validation Via New Study Australian psychedelics company MindBio Therapeutics Corp. was granted approval by both the Ethics committee and the Clinical Trials Registry to begin the world's first Phase 2a take-home LSD microdosing trial in patients with Major Depressive Disorder (MDD).
EXCLUSIVE: MDMA Therapy Experts Debate Upcoming Approval And Psychedelic Market Opps
In the current psychedelics landscape, one of the most important topics is compound legality.  While it's possible that MDMA-assisted therapy will eventually be federally approved in the U.S., what should investors consider when looking at a prospective business?
Psyched: MDMA Therapy Advances With FDA, Alternatives For Alcohol Addiction, Prince Harry In The Spotlight And More
MDMA Therapy For PTSD Nearing Legalization In U.S. And Worldwide, MAPS Releases Promising Data
High-Profile Highs: How Celebrity Advocacy Is Transforming Society's Views On Psychedelics And Cannabis
As part of the recent so-called “psychedelics renaissance,” numerous celebrities, global 
Psyched: Australia As Psychedelics Hub, Advanced Scans Of Brain On DMT, New PAC For Congressional Influence, 9 States Advancing Bills & More
Australia: Enveric, FSD Pharma, Psyence & Others Advance Businesses
Psychedelics Producer Lucy Scientific Discovery Partners With Pramantha Group For Funding: What's Next?
Early-stage psychedelics manufacturing company Lucy Scientific Discovery Inc.
Psychedelics Company Conducts Investigation Into Potential Naked Short Selling Of Its Stock
FSD Pharma Inc. (NASDAQ: HUGE) has renewed a service agreement with shareholder intelligence services provider ShareIntel LLC to assist in ongoing
Two Major Psychedelics Companies Take Novel Chemical Entity Patent Battle To Federal Court
Clinical-stage biopharma company Reunion Neuroscience Inc. (NASDAQ: REUN) filed a lawsuit against drug discovery business Mindset Pharma Inc. (OTCQB: MSSTF) in the District Court of New Jersey.
Who's Who At The Benzinga Psychedelics Capital Conference? Check Out These CEOs & Meet Them In Person
This year’s edition of the Benzinga Psychedelics Capital Conference, THE place to be for those interested or already involved in the space, will take place on April 13, following our established Cannabis Capital Confere
Here Are The Year's Highest Priced Psychedelics Stocks In US Markets
After everything that's happened in the last several years, we believe it's safe to say that the psychedelic renaissance is a reality, one that Benzinga has consistently reported on.  
Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More
Two Bills Approved By Hawaii Senators With Governor's Endorsement Hawaii Senate Ways and Means Committee approved a pair of bills aiming to promote and investigate the therapeutic potential of MDMA and psilocybin as an alternative to treat mental health conditions.
[Video] Tech Millionaires Brock Pierce, Jeremy Gardner Venture Into Psychedelics, Seek To Address Mental Health Issues
Jeremy Gardner and Brock Pierce, managing partners at Mystic Ventures stopped by Benzinga Cannabis Insider where hosts Javier Hasse and
Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback Earlier this week, three bills were introduced and added to the list of measures calling for some sort of psychedelics legalization, while some of the already filed ones continue progressing and others get a thumbs down.
Cube Psytech To Buy Psychedelics Company With Data On 200 Species Of Mushrooms
Canadian biopharma psychedelics company Cube Psytech Holdings agreed to acquire Translational Life Sciences (TLS). 
EXCLUSIVE: Social Equity, Adult-Use, Commercialization & Regs For Psychedelics, Lessons From Cannabis
(Part three of a three-part series) See previous stories:
Psyched: Australia Legalizes Psychedelics Therapy, BC's Decrim, State Bills, Millions For Trials & Clinics
Australian Health Authority To Allow Psilocybin And MDMA-Assisted Therapy For Depression, PTSD Beginning on July 1, 2023, medicines containing psilocybin and MDMA can be prescribed by specifically authorized psychiatrists to treat certain mental health conditions, such as post-traumatic stress disorder and psilocybin for treatment-resistant depression.
MDMA News: Optimi's New Drug Now Available, Revive Advances Transdermal Patch Evaluations
Considering MDMA will likely be the first psychedelic to receive FDA approval for psychotherapeutic use to treat serious mental health conditions such as PTSD, seve
Silo Pharma, Mindset Pharma, Terran Biosciences Receive Psychedelic Treatments Patents, IP Portfolios Expanded
Silo Pharma Sees Growth In IP With New US Patent For Novel Ketamine Method On Stress-Induced Affective Disorders
'Sea Change': Irwin Naturals, Numinus And Field Trip Discuss Psychedelics At Cantor Webinar
Cantor Fitzgerald's Pablo Zuanic hosted a virtual panel discussion about the psychedelics industry with three ketamine therapy providers: Irwin Naturals (OTCMKTS: IWINF)’ CEO Klee Irwin, Field Trip H&W (OTCMKTS: FTHWF)’s co-founder and director Mujeeb Jafferi and Numinus (OTCMKTS: NUMIF)’ CEO Payton Nyquvest.